| ||||||||||||||||||||||
| ||||||||||||||||||||||
Entries tagged "Roche"Alleged grifter's marks land on the blockThe latest fraud in the news did not defraud investors, but instead corporations that later sold some of the assets involved in the scams. Is Eli Lilly the next pharma to be swallowed?As consolidation in the pharma business continues, Eli Lilly could find itself becoming a target. Deal Stocks: Is M&A Monday back?Despite the return of M&A Monday, the markets failed to rally -- not even merger adviser Morgan Stanley's stock benefited from the news. Genentech: Tied to the tracks?Roche said early Friday it was lowering its offer to $86.50 a share and taking it hostile. Genentech's Levinson dishes, but not on RocheAs expected, Genentech Inc. CEO Art Levinson and other executives, appearing at the annual J.P. Morgan Chase & Co. healthcare conference in San Francisco, were tight-lipped Tuesday about the pending Roche Holding AG $44 billion acquisition offer. In his presentation Levinson steered clear of the topic completely, and in a packed Q&A session afterwards, he and his assembled team declined to comment on the latest reports of Roche possibly preparing a new bid. ... No Avastin bump for GenentechSwiss drug giant Roche Holding AG said Tuesday it's still committed to a "negotiated settlement" in its pursuit of Genentech Inc. The remark came from CEO Severin Schwan during the firm's quarterly earnings call. In July Roche bid $43.7 billion, or $89 a share, for the 44% it doesn't already own. Genentech's board said it was too low but left the door open to higher offers. ... Genentech stays mum on Roche bidGenentech Inc. reported third-quarter earnings late Tuesday. Thanks to its cancer drugs, the news was generally good for the biotech giant. But conference call participants interested in deal news weren't satisfied because Genentech management refused to comment on the progress of the proposed takeover by Roche AG, Genentech's majority owner, which has moved to buy out the 44% it doesn't own for $89 a share. ... The Deal newsweekly, week of Sept. 1Maybe this is the last issue of the summer, or the first issue of the fall. Whatever it is, our preoccupations remain pretty much the same: The financial crisis hangs in there like a particularly ugly summer cold. ... Genentech pushes back against RocheExecutives evaluating the bid say they can give no assurance of approving the transaction. Roche proposes $43.7B Genentech buyoutSwiss drugmaker Roche Holding AG on Monday announced a $43.7 billion offer for the outstanding shares in biotech Genentech Inc. to assist its hunt for new medicines. ... Deal International: News on Eramet, Roche, Atos Origin and moreStay tuned to TheDeal.com and Deal International for updates to these stories and more. Eramet-TinfosTopping headlines out of Europe Tuesday morning, French miner Eramet said it had bought Norway's Tinfos for €593 million ($937 million) in cash and shares. ... Top tagsYou have executed a tag search on Dealscape. On the left,you will find a comprehensive list of stories tagged "Roche." Below are the most-popular tags for Dealscape. On the right of the page you will find a search box to dig deeper into our content.
 Deal Video
    Community
 Elsewhere on The Deal.comDealwatch
The Deal MagazineCorporate Dealmaker
The Deal VideoCategories
Blog roll
Archives
| ||||||||||||||||||||||
| ||||||||||||||||||||||
